Many patients with Afib and high stroke risk are not anticoagulated

By  |  April 27, 2010 | 

In this retrospective analysis of over 170,000 patients with Afib, of the 18% who were at high risk of stroke (CHADS2 score of 3-6), only 42% of them were receiving anticoagulation with warfarin. The % on warfarin was not much different from those in low risk group (CHADS2 score of 0; 40% were on warfarin) or in the moderate risk group (CHADS2 score of 1-2; 44% were on warfarin). Only about a third of patients in each group received continuous warfarin for 6 months. This study highlights the inadequacies of treating high risk stroke patients with warfarin therapy, and the difficulties in keeping them on continuous therapy (abstract)

Leave A Comment

About the Author:

Danielle Scheurer
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.


Related Posts

By  | June 18, 2018 |  0
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis.  ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
By  | July 5, 2016 |  0
What comes to mind when you think of getting CME? I bet most of you would say sitting in an auditorium, whether that be during your local grand rounds or at our professional society meeting, like Hospital Medicine 16 in sunny San Diego this past March. Hanging out in the Twitterverse? Probably not so much… […]
By  | December 3, 2013 |  1
As a nurse practitioner in hospital medicine I have multiple opportunities to interact with all sorts of physician hospitalist colleagues, hospital medicine group leaders, quality officers etc.  Often their interactions with me take on a certain wary curiosity, like I am some exotic monkey or another creature that is unfamiliar to them.  If I am […]